Diabetes, Heart and Cardiovascular Diseases News Chronicle Diabetes, Cardiovascular and Heart Diseases. Article 20
Published on June 19, 2016 at 9:05 AM


Treatment With Revita

Revita, a new revolutionary treatment technology was developed by Fractyl Laboratories Inc., a US based company, to make body absorb and process sugar by burning gut. Scientists are using balloon of size less than rice grain in this process. The treatment takes 90 minutes and performed under sedition. Scientists think forming new hormone cells by burning non hormone producing cells. The new cells formed in our body can release required hormones and subsequently improve processing and absorption of glucose. University College Hospital, London are going to perform first Ravita treatment. But the scientists could not confirm about relief from diabetes after treatment but trials done on 22 Chile citizens were successful.

       
Post a message on social media and mail to your friend and doctor to resolve your health condition. Article address TO LINK on your social media is (copy and past the code below):

Also related to this story
1. SR10171 Drug For The Treatment Of Bone Disease And Diabetes
2. Risks To Diabetes Induced Cognitive Impairment
3. About Coronary Heart Disease (CHD)

 

Treatment With Sanofi's LixiLan

France based Sanofi developed a new diabetes combination therapy drug, LixiLan, developed with Zealand Pharma. The drug got approval in some countries with the trade name Lyxumia. Two trials in phase III were conducted with LixiLan drug, LixiLan-O and LixiLan-L, to check the efficacy and safety of the Sanofi's once-daily single injection type combination drug for a period of 30 weeks. Both the studies showed better reduction in HbA1c from baseline compared with glargine and lixisenatide. The phase III clinical trials of LixiLan diabetes drug were successful. As reported by Sanofi, the side effects are

The results of both trials were included in regulatory submissions in the US and Europe. FDA decision is expected in August and EMA decision early next year.

       
Post a message on social media and mail to your friend and doctor to resolve your health condition. Article address TO LINK on your social media is (copy and past the code below):

Also related to this story
1. Risks With Adrenal Tumors NFATs
2. Risks With Heart Disease

 

Trials With ACCORDION

ACCORDION trial was based on 1,310 individuals with type 2 diabetes (T2D) and diabetic retinopathy (related to eye and vision). This trial was a continuation of ACCORD trial started 4 years back. Development of diabetic retinopathy was studied on individuals who received intensive blood glucose therapy and kept good blood glucose levels even after 4 years. It was found that the good glycemic control levels failed to reduce risk for cardiovascular disease but progression of retinopathy was reduced by one-third. The findings indicates individual can get positive and long-lasting effects on small blood vessels with the tight control of glycemic levels. Fenofibrate might be good to control diabetic retinopathy and some countries approved it. Emily Chew, M.D., is the lead author of the study, says good glycemia or blood sugar level is good for eye health. The study findings were published in Diabetes Care.

       
Post a message on social media and mail to your friend and doctor to resolve your health condition. Article address TO LINK on your social media is (copy and past the code below):

Also related to this story
1. Trials With Toujeo
2. Risks With High BMI

 

Study Of Automated OCL Insulin System

Incidents of nocturnal hypoglycemia in children and adolescents can be reduced by using an automated insulin feedback controller as part of OCL. The study was conducted on Medtronic Android-based PID-IFB closed-loop blood glucose control system for practical usage during multiple nights at a diabetes camp. The product contains

The study results shows

The study was conducted by Trang Ly, PhD and the study findings were published in Diabetes Technology & Therapeutics (DTT).

       
Post a message on social media and mail to your friend and doctor to resolve your health condition. Article address TO LINK on your social media is (copy and past the code below):

Also related to this story
1. About Insulin Pump Therapy
2. Risks With Fine Dust
3. Risks With Heart Attack

 

Benefits With Yogurt
A study conducted by Harvard School of Public Health found that increased consumption of yogurt will lower the risk to type 2 diabetes (T2D). Daily consumption of 28 grams of yogurt will lower risk to type ii diabetes (T2D) by 18%. Yogurt is rich with elements that help us in regulating digestion and intestinal function. They are

       
Post a message on social media and mail to your friend and doctor to resolve your health condition. Article address TO LINK on your social media is (copy and past the code below):

Also related to this story
1. Device To Release Drugs In Eye
2. Benefits With Alcohol Free Blueberry Blackberry Wine
3. Study Of Liraglutide Drug On Heart Failure

 

Usability Study Of CONTOUR NEXT ONE
Ascensia Diabetes Care manufactures CONTOUR NEXT ONE glucose monitoring systems. A study was conducted by Dr Timothy Bailey (AMCR Institute, San Diego), lead investigator, to asses usability of CONTOUR NEXT ONE blood glucose meter with 43 individuals suffering with type 1 diabetes (T1D) and type ii diabetes (T2D) condition. The study showed that

       
Post a message on social media and mail to your friend and doctor to resolve your health condition. Article address TO LINK on your social media is (copy and past the code below):

Also related to this story
1. Device To Predict Diabetes
2. Benefits With Coffee Consumption
3. Risks To Heart Attack And Diabetes Before Menopause

 

Categories

Sitemap 1   Sitemap 2   Sitemap 3   Sitemap 4

 

Diabetes News Chronicle does not provide medical advice, diagnosis or treatment. Information in Diabetes News Chronicle is to support and not to replace medical advice given by surgeon or physician or doctor. Published article is not a medical advice by the OWNER of "Diabetes News Chronicle" website or by the AUTHOR of the article.


Published by Jammi Vasista, Chennai, India.
Email Jammi[no-space]Vasista1991[at]gmail[dot]com
Phone 91-944-578-3182.
Address Diabetes News Chronicle, No 40, Kaveri Street, Rajaji Nagar, Villivakkam, Chennai, India. Pin : 600049.